The purpose of this study is to compare the efficacy of Kovacaine Mist, Tetracaine only, and Placebo for inducing pulpal anesthesia of the maxillary teeth in adults.
The study will employ a multi-center, randomized, double-blind, placebo-controlled, parallel-groups design to assess the safety and efficacy of Kovacaine Mist delivered intranasally for inducing pulpal anesthesia of maxillary teeth numbers 4 to 13 (maxillary right second premolar to maxillary left second premolar) sufficient to allow completion of the Study Dental Procedure. A total of 140 subjects, randomized 2:2:1 (Kovacaine Mist:Tetracaine alone:Placebo) will be enrolled to achieve 125 completed subjects; a total of 50 Kovacaine Mist subjects, 50 tetracaine alone subjects and 25 placebo subjects. Recruitment will be from diverse dental patient populations. At the two study sites, a balanced enrollment of 70 subjects each is planned to allow for a potential 10% drop-out rate.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
26
3 unilateral intranasal sprays per dose
3 unilateral intranasal sprays per dose
3 unilateral intranasal sprays per dose
University of Maryland, Baltimore
Baltimore, Maryland, United States
Family and Cosmetic Dentistry
Salt Lake City, Utah, United States
Jean Brown Research
Salt Lake City, Utah, United States
Completion of the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic (Yes/no).
Time frame: at 15 minutes with a 3 minute window
Intraoral Soft-tissue Anesthesia (Yes/no)
Number of patients who reported no pain when incisive papilla and greater palatine foramen soft-tissue was tested with a probe
Time frame: at 15 minutes with a 3 minute window
Number of Participants With Heart Rate Higher Than 125 Bpm
Time frame: at any time within 120 minutes following drug administration
Number of Participants With Heart Rate Lower Than 50 Bpm
Time frame: at any time within 120 minutes following drug administration
Number of Participants With an Increase From Baseline in Systolic Blood Pressure Greater Than or Equal to 25 mm Hg and to a Value Higher Than 160 mm Hg
Time frame: at any time within 120 minutes following drug administration
Number of Participants With a Decrease From Baseline in Systolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Lower Than 90 mm Hg
Time frame: at any time within 120 minutes following drug administration
Number of Participants With an Increase From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Higher Than 90 mm Hg
Time frame: at any time within 120 minutes following drug administration
Number of Participants With a Decrease From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Lower Than 90 mm Hg
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: at any time within 120 minutes following drug administration
Absolute Maximum Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure
Time frame: from baseline to 120 minutes following drug administration
The Profile Over Time of Heart Rate
Time frame: from baseline to 120 minutes following drug administration
Alcohol Sniff Test
The change from screening in the the distance from the nose (in centimeters) that a patient is able to detect the smell of an alcohol swab.
Time frame: administered at approximately 24 hours after drug administration
The Profile Over Time of Systolic Blood Pressure
Time frame: from baseline to 120 minutes following drug administration
The Profile Over Time of Diastolic Blood Pressure
Time frame: from baseline to 120 minutes following drug administration
Absolute Maximum Change From Baseline in Heart Rate
Time frame: from baseline to 120 minutes following drug administration